Hepatocellular carcinoma, the most common primary cancer of the liver, is notoriously difficult to treat once it becomes advanced. Even when chemotherapy or targeted treatment initially slows tumor growth, a resilient population of cancer cells can survive, adapt and eventually return in a more aggressive form. A study by Xu, Huang, Zhang and colleagues, published in Nature Communications, identifies a molecular mechanism that may help explain this behavior: phosphorylation of the endoplasmic-reticulum chaperone BiP by the stress-response kinase p38β.
The findings place p38β at the center of a biological switch that allows liver cancer cells to preserve stem-like properties while avoiding a cellular alarm system known as the unfolded protein response, or UPR. Cancer cells often manufacture unusually large amounts of proteins, remodel their metabolism and endure oxygen deprivation, creating intense stress inside the endoplasmic reticulum, the cellular compartment responsible for folding and processing newly made proteins. Under normal circumstances, this stress activates the UPR, which either restores protein-folding capacity or, if damage is too severe, triggers programmed cell death.
BiP, also known as HSPA5 or GRP78, is one of the UPR’s key regulators. It acts as a molecular chaperone, helping proteins fold correctly and monitoring stress-sensing pathways embedded in the endoplasmic-reticulum membrane. When unfolded proteins accumulate, BiP changes its interactions with these sensors, including PERK, IRE1 and ATF6, initiating a coordinated response. This response can temporarily protect a cell, but persistent or excessive UPR activation may become lethal. The new research indicates that p38β-mediated phosphorylation changes BiP’s behavior in a way that dampens this protective checkpoint.
Phosphorylation is a reversible chemical modification in which a phosphate group is attached to a protein, often altering its shape, stability, location or interactions with other molecules. Protein kinases such as p38β perform this modification in response to intracellular signals, including inflammation, oxidative stress and other forms of environmental pressure. According to the study, p38β targets BiP and thereby suppresses UPR activation in hepatocellular carcinoma cells. Rather than allowing endoplasmic-reticulum stress to escalate toward cell death, the modified BiP appears to help malignant cells maintain a state of controlled adaptation.
That adaptation may be particularly important for cancer stemness. Cancer stem-like cells are not necessarily identical to normal tissue stem cells, but they share properties such as self-renewal, developmental flexibility and the ability to generate diverse tumor-cell populations. In liver cancer, these cells are widely considered a major source of tumor initiation, recurrence and treatment resistance. By sustaining stemness-associated programs, the p38β–BiP pathway could help a small fraction of tumor cells survive therapy and later repopulate the tumor.
The mechanism also offers an explanation for chemoresistance. Many anticancer drugs damage DNA, disrupt replication or intensify metabolic and protein-folding stress. A cancer cell that can suppress the UPR’s lethal consequences may tolerate these pressures more effectively than a less adaptable cell. The study’s central conclusion is that p38β-dependent BiP phosphorylation provides hepatocellular carcinoma with precisely this advantage, allowing tumor cells to withstand treatment while preserving the biological traits linked to relapse.
The work is significant because it connects three processes that are often studied separately: stress signaling, cancer-cell plasticity and drug resistance. p38 kinases have long been associated with inflammatory and stress responses, while BiP has been examined as a marker and regulator of endoplasmic-reticulum stress. Linking a specific kinase-driven modification of BiP to stemness and chemotherapy resistance suggests that the interaction is not merely a consequence of tumor stress, but may actively organize the cancer cell’s survival strategy.
The findings also point toward a potential therapeutic vulnerability. In principle, blocking p38β activity, preventing BiP phosphorylation or restoring an appropriate UPR response could make tumor cells less able to tolerate chemotherapy. Such strategies would require careful development, however. The p38 family participates in normal immune, inflammatory and tissue-repair processes, while BiP is essential for healthy cells that experience physiological protein-folding demands. A treatment that interferes with this pathway would need to distinguish malignant stress adaptation from normal cellular maintenance.
Future studies will be needed to determine how broadly the mechanism operates across patient tumors, whether BiP phosphorylation can be measured reliably as a biomarker and which treatment combinations are most effective. It will also be important to establish whether p38β inhibition can selectively eliminate stem-like cancer cells without causing unacceptable toxicity. Nevertheless, the study offers a compelling molecular explanation for why some liver tumors remain stubbornly resistant: they may be using a kinase-controlled modification of a central stress chaperone to keep their internal alarm system quiet while preserving the capacity to survive, renew and return.
Subject of Research: p38β-mediated BiP phosphorylation, unfolded protein response suppression, stemness and chemoresistance in hepatocellular carcinoma
Article Title: p38β-mediated BiP phosphorylation drives stemness and chemoresistance by suppressing UPR activation in hepatocellular carcinoma
Article References: Xu, L., Huang, I.B., Zhang, M. et al. p38β-mediated BiP phosphorylation drives stemness and chemoresistance by suppressing UPR activation in hepatocellular carcinoma. Nat Commun (2026). https://doi.org/10.1038/s41467-026-76073-7
Image Credits: AI Generated
DOI: 10.1038/s41467-026-76073-7
Keywords: hepatocellular carcinoma, liver cancer, p38β, BiP, HSPA5, GRP78, phosphorylation, unfolded protein response, endoplasmic reticulum stress, cancer stemness, chemoresistance, cancer biology
